ArticleCureus2025
Hydroxychloroquine-Induced Renal Phospholipidosis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal phospholipidosis is a rare condition in which excessive phospholipids accumulate in the lysosomes of the renal cells, leading to renal dysfunction. Historically, phospholipidosis has been described in the context of inherited disorders of lysosomal phospholipid metabolism such as Fabry disease. It is now known that many medications can cause excessive phospholipid accumulation, leading to cellular dysfunction. We present a case of hydroxychloroquine-induced renal phospholipidosis in a 79-year-old female patient with Sjogren's disease who had been on hydroxychloroquine for several years and developed nephrotic range proteinuria. She underwent a renal biopsy that showed myeloid (lamellar) bodies within podocytes, a morphological sign of phospholipidosis. Immunofluorescence staining for other potential causes was negative, making it a case of drug-induced phospholipidosis. This patient also had underlying chronic kidney disease stage II. This case raises a question of whether an underlying impaired renal function contributes to the risk of developing drug-induced phospholipidosis, as well as the importance of timely and accurate diagnosis to prevent further harm and to increase the chances of renal recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.